TriSalus Life Sciences, Inc. (TLSI) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, TriSalus Life Sciences reported revenue of $45.2M, up 53.4% from $29.4M the year before. Net income was -$39.2M (a -86.9% net margin), or -$1.84 per diluted share. Gross margin was 84.6% and operating margin was -59.7%. Operating activities generated -$18.0M of cash, leaving -$18.9M of free cash flow. At fiscal year end, TriSalus Life Sciences held $35.3M in total assets against $69.2M in total liabilities, including $20.4M of cash and equivalents.
Open the full interactive TriSalus Life Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
TriSalus Life Sciences Key Stats
| Share Price | $4.00 |
|---|---|
| Market Cap | $233.2M |
| Revenue YoY Growth | +53.4% |
| 52-Week Range | $2.52 – $7.50 |
| Shares Outstanding | 58.3 million (basic, 2026 Q2) |
TriSalus Life Sciences Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $18.5M | $29.4M | $45.2M |
| Cost of Goods Sold | — | — | $2.6M | $4.1M | $7.0M |
| Gross Profit | — | — | $15.9M | $25.3M | $38.2M |
| Operating Income | -$3.0M | -$2.7M | -$54.1M | -$36.2M | -$26.9M |
| Pre-Tax Income | $4.8M | $6.1M | -$59.0M | -$30.0M | -$39.2M |
| Income Tax | $0 | $570,854 | $9,000 | $6,000 | $7,000 |
| Net Income | $4.8M | $5.5M | -$59.0M | -$30.0M | -$39.2M |
| Diluted EPS | $0.15 | $0.19 | -$6.73 | -$1.31 | -$1.84 |
TriSalus Life Sciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $11.6M | $13.2M | $8.9M | $11.4M |
| Net Income | -$10.8M | -$9.8M | $1.5M | -$9.2M |
| Diluted EPS | -$0.96 | -$0.26 | $0.03 | -$0.16 |
TriSalus Life Sciences Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $200,884 | $153,563 | $11.8M | $8.5M | $20.4M |
| Current Assets | $525,884 | $359,892 | $20.9M | $20.7M | $32.2M |
| Total Assets | $250.5M | $20.2M | $25.7M | $24.0M | $35.3M |
| Current Liabilities | — | $2.5M | $14.7M | $10.2M | $11.5M |
| Total Long-Term Debt | — | — | — | $22.1M | $33.0M |
| Total Liabilities | $17.3M | $13.7M | $51.7M | $49.9M | $69.2M |
| Shareholders' Equity | -$16.7M | -$13.3M | -$25.9M | -$25.9M | -$33.9M |
TriSalus Life Sciences Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$1.7M | -$2.7M | -$50.0M | -$40.8M | -$18.0M |
| Cash From Investing | $60,000 | $233.2M | -$2.1M | -$345,000 | -$838,000 |
| Cash From Financing | $544,000 | -$230.5M | $54.6M | $37.9M | $30.8M |
| Free Cash Flow | — | — | -$50.6M | -$41.2M | -$18.9M |
Figures from TriSalus Life Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full TriSalus Life Sciences financials page for every line item.
TriSalus Life Sciences Company Profile
| Ticker | TLSI |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Westminster, Colorado |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001826667 |
Frequently Asked Questions
What was TriSalus Life Sciences' revenue in fiscal 2025?
TriSalus Life Sciences (TLSI) reported revenue of $45.2M for fiscal 2025.
What is TriSalus Life Sciences' annual revenue history?
TriSalus Life Sciences' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $18.5M; 2024: $29.4M; 2025: $45.2M.
What was TriSalus Life Sciences' net income in fiscal 2025?
TriSalus Life Sciences reported net income of -$39.2M for fiscal 2025.
What was TriSalus Life Sciences' earnings per share (EPS) in fiscal 2025?
TriSalus Life Sciences' diluted EPS was -$1.84 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did TriSalus Life Sciences generate in fiscal 2025?
TriSalus Life Sciences generated -$18.9M of free cash flow in fiscal 2025.
What was TriSalus Life Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), TriSalus Life Sciences reported revenue of $11.4M.
How much debt does TriSalus Life Sciences have?
TriSalus Life Sciences reported $33.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of TriSalus Life Sciences are outstanding?
TriSalus Life Sciences reported a weighted average of 58.3 million basic shares outstanding in 2026 Q2.
What is TriSalus Life Sciences' market cap?
Based on its latest closing price, TriSalus Life Sciences (TLSI) has a market capitalization of about $233.2M.
When does TriSalus Life Sciences' fiscal year end?
TriSalus Life Sciences' fiscal year end, as registered with the SEC, is December 31.
Where is TriSalus Life Sciences headquartered?
TriSalus Life Sciences lists its business address in Westminster, Colorado in its SEC filings.
TriSalus Life Sciences Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →